StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — Swati Hotkar, Nirmal Bang Securities

BUYEmcure Pharmaceuticals Limited
Emcure Pharmaceuticals share price target & all analyst calls

bySwati Hotkar, Nirmal Bang SecuritiesHorizon: 1–3 months2 Jun 2026via NDTV Profit (Live)

Entry₹1,630Stated
Target₹1,750
Total upside +7.36% (call closed)
Stop lossNot given
Exit—No position was opened
ExpiredNA
Follow Swati Hotkar for new calls(50% target hit, 18 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 45 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 2 Sept 2026
13 supporting3 neutral1 opposing
Supports the BUY call (13)

3 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·28 Aug · 5d ago

Emcure Pharma receives USFDA EIR for Sanand facility; regulator classifies it as 'VAI'; here's what it means

NewsCnbc-Tv18·8 Aug · 4w ago

(opens in new tab)

Emcure Pharmaceuticals Q1 Results: Net profit rises 42%, international business aids topline growth

NewsCnbc-Tv18·6 Aug · 4w ago

(opens in new tab)

Emcure Pharma Q1: Net Profit Jumps 42%; CEO Satish Mehta Appointed As Chairman

NewsNdtv-Profit·6 Aug · 4w ago

(opens in new tab)

1 other SEBI-registered advisor has an active short-term BUY call on this stock

Advisor consensus · same horizon·8 Jul · 2mo ago

Neutral / worth noting (3)

EMCURE PHARMACEUTICALS L Share Price

NewsGoogle News·25 Aug · 1w ago

(opens in new tab)

Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·6 Aug · 4w ago

(opens in new tab)
Weighs against the BUY call (1)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Emcure Pharmaceuticals

All analyst calls on Emcure Pharmaceuticals

More from Swati Hotkar, Nirmal Bang Securities

Every call and its outcome